PD-L1 expression in early NSCLC: Interpreting the data so far | Heather Wakelee & Nasser Altorki Published 2022-05-05 Download video MP4 360p Download video MP4 720p Recommendations 55:10 CAR-T Cell Therapy: Now and in 2030 | Laboratory Medicine and Pathology in Individualized Medicine 31:51 Lung Cancer Breakout: Breakthrough treatments for longer life 02:12 Why I Went into Medicine, Heather Wakelee, MD 27:32 Lung Cancer Staging 02:07 Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative Biolabs 1:28:15 Day in the life - Ophthalmologist (Eye Surgeon/Eye Medical Doctor). 23:44 Elon Musk's Bionic Eyes Are Here. 1:27:19 The Art of Aging Well 2:24:07 2023 HMS/HSDM White Coat Ceremony 1:28:26 Cancer Metabolism: From molecules to medicine 1:32:16 An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar 01:16 Explaining Immunotherapy, PD-L1 and PD-1 2:22:00 186 - The Opioid Crisis with Patrick Radden Keefe 09:42 Mayo Clinic: William Palmer, M.D. - Hereditary Hemochromatosis 16:43 Cancer Staging with the IASLC Lymph Node Map 31:08 FANTASTIC STEM CELLS and Where to Find Them with Shiri Gur-Cohen 18:58 PD-L1 Testing by Immunohistochemistry 1:44:58 Why Sleep Matters 01:42 Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 Expression Similar videos 03:18 Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab 49:11 How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLC 59:37 Drs. Altorki & Spicer discuss #NSCLC #Immunotherapy at #ThoracicSummit2022 - https://bit.ly/3BXcsbV 1:08:00 Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC? 04:48 KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC 03:08 Choosing immunotherapy as front line therapy for non-actionable NSCLC 02:13 mNSCLC with both PD-L1 and an Actionable Mutation 05:23 KEYNOTE-598: pembro + ipi in metastatic NSCLC 27:13 Dr Jatin | Optimizing Treatment for First Line NSCLC 01:27 Nasser Khaled Altorki, MD 59:26 WATCH NOW - New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Da… 05:30 Chemo + I-O in Frontline mNSCLC: PD-L1 TPS Greater Than 50% 1:01:06 IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLC 06:22 Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC 17:12 Dr Taha Sethiwala | Optimizing Treatment for first line NSCLC 03:44 Immunotherapy as combination and neoadjuvant therapies in NSCLC 33:39 Local Lung Cancer | 2022 OneOncology Conference 21:08 Pathologic testing for ALK and ROS1 aberrations in NSCLC | Frédérique Penault-Llorca More results